Clinical Report: Mastering Myopia

Overview

Recent trends in myopia management highlight the importance of identifying pre-myopes and utilizing effective treatments to delay myopia onset. New research indicates that treatments such as low-concentration atropine and red light therapy can significantly slow myopia progression in children.

Background

Myopia, or nearsightedness, is a growing public health concern, particularly among children. Understanding the risk factors for myopia development and the efficacy of various treatment options is crucial for healthcare professionals to implement effective management strategies. As myopia prevalence continues to rise globally, innovative approaches to treatment are essential for improving patient outcomes.

Data Highlights

No numerical data available in the source material.

Key Findings

• Pre-myopes are identified as children with specific risk factors, including family history and visual habits.
• The Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error (CLEERE) study established a pre-myopia threshold of less than +0.75D at ages 6-7 years.
• Recent studies suggest a higher pre-myopia threshold of +1.50D to +2.00D for Chinese children.
• Randomized controlled trials show that treatments can delay myopia onset by approximately 50%.
• Red light therapy has demonstrated efficacy in slowing myopia progression in various populations.
• Combination treatments are being explored, although caution is advised with atropine use.

Clinical Implications

Healthcare providers should actively screen for pre-myopia in children to initiate timely interventions. Effective communication with patients and their families regarding treatment options and expectations is essential for adherence and optimal outcomes.

Conclusion

The evolving landscape of myopia management underscores the need for proactive strategies to address this public health issue. Continued research and clinical application of innovative treatments will enhance the effectiveness of myopia control.

References

1. Flitcroft DI, He M, Jonas JB, et al., Invest Ophthalmol Vis Sci, 2019 -- IMI - Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies
2. Zadnik K, Sinnott LT, Cotter SA, et al; CLEERE Study Group, JAMA Ophthalmol, 2015 -- Prediction of Juvenile-Onset Myopia
3. Chen Z, Gu D, Wang B, et al., J Glob Health, 2023 -- Significant myopic shift over time: Sixteen-year trends in overall refraction and age of myopia onset among Chinese children
4. Wang J, Qi Z, Feng Y, et al., Br J Ophthalmol, 2024 -- Normative value of hyperopia reserve and myopic shift in Chinese children and adolescents
5. Jethani J, Efficacy of low-concentration atropine (0.01%) for myopia progression, 2022
6. contact lens spectrum — Mastering Myopia: Starting Strong: Managing Myopia from the Onset
7. Contact Lens Spectrum — Mastering Myopia: Starting Strong: Managing Myopia from the Onset
8. Contact Lens Spectrum — MASTERING MYOPIA
9. contact lens spectrum — Mastering Myopia: Innovations and Future Directions
10. Mastering Myopia: Starting Strong: Managing Myopia from the Onset
11. MASTERING MYOPIA
12. Untitled
13. Interventions to slow the progression of short-sightedness in children | Cochrane
14. Five-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 4 Report - ScienceDirect
15. Axial Growth and Myopia Progression After Discontinuing Soft Multifocal Contact Lens Wear | Ophthalmology | JAMA Ophthalmology | JAMA Network
16. Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years | Scientific Reports
17. Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial | Trials | JAMA Ophthalmology | JAMA Network
18. Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial | Trials | JAMA Ophthalmology | JAMA Network
19. Frontiers | Value of adding 0.01% atropine with orthokeratology for myopia in children: an updated meta-analysis of randomized controlled trials
20. Benefits and risks of orthokeratology treatment: a systematic review and meta-analysis - PMC